Table 1 Top 10 mergers and acquisitions of 2015
From: Biopharma deal-making in 2015: changing the pharma landscape
Rank | Month | Acquirer | Target | Deal value |
|---|---|---|---|---|
1 | November | Pfizer | Allergan | $160 billion |
2 | July | Teva Pharmaceutical | Allergan's generics business | $40.5 billion |
3 | May | AbbVie | Pharmacyclics | $21 billion |
4 | September | Pfizer | Hospira | $17 billion |
5 | April | Valeant Pharmaceuticals | Salix Pharmaceuticals | $15.8 billion |
6 | June | Alexion Pharmaceuticals | Synageva BioPharma | $8.4 billion |
7 | September | Endo International | Par Pharmaceutical | $8.1 billion |
8 | August | Celgene | Receptos | $7.2 billion |
9 | November | Shire | Dyax | $6.6 billion* |
10 | February | Shire | NPS Pharmaceuticals | $5.2 billion |
